Praktické lékárenství – 2E/2021

www.praktickelekarenstvi.cz e26 AKTUÁLNÍ FARMAKOTERAPIE Neuroprotektivní účinky statinů PRAKTICKÉ LÉKÁRENSTVÍ LITERATURA 1. AlamA, Hana Z, Jin Z, Suen KC, Ma D. Surgery, neuroinflammation and cognitive impairment. EBioMedicine 2018; 37: 547–556. 2. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sille- sen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Redu- ction in Cholesterol Levels (SPARCL) Investigators. High–dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559. 3. Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar A. The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanis- tic review. Biofactors 2019 Dec 17. doi: 10.1002/biof.1597. 4. Bednařík J, Vlčková E, Horák T. Statinová myopatie. Neurol. praxi 2017; 18(1): 15–19. 5. Ciurleo R, Bramanti P, Marino S. Role of statins in the treatment of multiple sclerosis. Phar- macol Res 2014; 87: 133–143. 6. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Dane- sh J, Smith GD, DeMets D, Evans S, Low M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercoc P, Schulz K, Sever P, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lan- cet 2016; 388: 2532–2561. 7. Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, Segatto M. Statins and the Brain: More than Lipid Lowering Agents? Curr Neuropharmacol 2019; 17(1): 59–83. 8. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, Zivin JA, Welch KM; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reducti- on in Cholesterol Levels study. Neurology 2008; 70: 2364–2370. 9. Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P. Long- -termmortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16- year follow-up results of a randomised factorial trial. Lancet 2018; 392(10153): 1127–1137. 10. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related ad- verse effects: a case series of 354 patients. Pharmacotherapy 2010; 30: 541–553. 11. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Ban- gham CHRM, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in se- condary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, pha- se 2 trial. Lancet 2014; 383(9936): 2213–2221. 12. Chen CJ, Ding D, Ironside N, Buell TJ, Elder LJ, Warren A, Adams AP, Ratcliffe SJ, James RF, Na- val NS, Worrall BB, Johnston KC, Southerland AM. Statins for neuroprotection in spontaneous intracerebral hemorrhage. Neurology 2019; 93(24): 1056–1066. 13. Chen PS, Cheng CL, Chang YC, Kao Yang YH, Yeh PS, Li YH. Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. Eur J Neurol 2015; 22: 773–780. 14. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cho- lesterol with statin therapy in people at low risk of vascular disease: meta-analysis of indi- vidual data from 27 randomised trials. Lancet 2012; 380: 581–590. 15. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in ol- der people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393: 407–415. 16. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92(2): 152–160. 17. Karki K, Knight RA, Han Y, et al. Simvastatin and atorvastatin improve neuro-logical out- come after experimental intracerebral hemorrhage. Stroke 2009; 40: 3384–3389. 18. Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzo M, Palladino R, Cha- taway J, Brescia Morra V. Therapeutic lag in reducing disability progression in relapsing-re- mitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvasta- tin. Mult Scler Relat Disord 2019; 28: 193–196. 19. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipopro- tein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analy- sis. BMJ 2003; 326(7404): 1423. 20. Lei C, Wu B, Liu M, Chen Y. Association between statin use and intracerebral hemorrh- age: a systematic review and meta-analysis. Eur J Neurol 2014; 21: 192–198. 21. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118. 22. Lokhandwala A, Hanna K, Gries L, Zeeshan M, Ditillo M, Tang A, Hamidi M, Joseph B. Preinjury Statins Are Associated With Improved Survival in Patients With Traumatic Brain Injury. J Surg Res 2020; 245: 367–372. 23. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, Backer G, Hegele RA, Hovin- gh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoĝlu L, Vladutiu GD, Gencert B, Stock JK, GinsbergHN, ChapmanMJ, European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018; 39(27): 2526–2539.